Study Points
- Back to Course Home
- Participation Instructions
- Review the course material online or in print.
- Complete the course evaluation.
- Review your Transcript to view and print your Certificate of Completion. Your date of completion will be the date (Pacific Time) the course was electronically submitted for credit, with no exceptions. Partial credit is not available.
Study Points
Click on any objective to view test questions.
Which is important to keep in mind regarding drug transporter systems (e.g., P-glycoprotein [P-gp])?
Which drug transport system has the most available data related to its effects on drug pharmacokinetics?
Which pair of direct oral anticoagulants are significantly metabolized by CYP3A4?
Which of the following medications is a strong inhibitor of CYP3A4?
Which of the following medications is a strong inducer of P-gp?
Which medication is most likely to decrease levels of a DOAC and increase thrombosis risk?
Which of the following medications is most likely to raise levels of a direct oral anticoagulant (DOAC) and increase bleeding risk?
Which of the following statements regarding DOAC interactions with nirmatrelvir/ritonavir is TRUE?
What is advised for patients receiving apixaban for venous thromboembolism treatment if a strong CYP3A4 and P-gp inducer is required?
What is generally advised for patients receiving apixaban for stroke prevention in atrial fibrillation and aspirin for cardiovascular primary prevention?
- Back to Course Home
- Participation Instructions
- Review the course material online or in print.
- Complete the course evaluation.
- Review your Transcript to view and print your Certificate of Completion. Your date of completion will be the date (Pacific Time) the course was electronically submitted for credit, with no exceptions. Partial credit is not available.